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Making quick promises of major biomedical breakthroughs based on exciting discoveries at
the bench is tempting. But the meandering path from fundamental science to life-saving
clinical applications can be fraught with many hurdles. Epigenetics, the study of poten-
tially heritable changes of gene function without modification of the underlying DNA
sequence, has dominated the biological research field during the last decade and
encountered a large public success. Driven by the unfolding of molecular biology and
recent technological progress, the term has evolved significantly and shifted from a con-
ceptual framework to a mechanistic understanding. This shift was accompanied by much
hype and raised high hopes that epigenetics might hold both the key to deciphering the
molecular underpinning of complex, non-Mendelian diseases and offer novel therapeutic
approaches for a large panel of pathologies. However, while exciting reports of biological
phenomena involving DNA methylation and histone modifications fill up the scientific
literature, the realistic clinical applications of epigenetic medicines remain somewhat
blurry. Here, we discuss the state of the art and speculate how epigenetics might contribute
to prognostic and therapy approaches in the future.Epigentic e the new “quantum”?
Every scientific sector has its own buzzwords e expressions
that ring a bell for everyone and which confer it with an aura
of futurist technology mixed with revolutionary insights and
solutions for most problems. As much as any obscure pro-
cedure in physics becomes credible by the simple addition of
the “quantum” particle to it, the term “epigenetics” is the new
all-round biological explanation for everything where& Innovation Centre (B
66; fax: þ45 72 62 02 85.
(S.J. H€afner).
g Gung University.
ublishing services by Else
/by-nc-nd/4.0/).classical genetics can't go, including the inter-generational
transmission of acquired traits, environmental impacts and
complex diseases.
Largely fueled by public media excitement, the epigenetic
hype has coincided with increasing disappointment from the
initial promises of genetics and the decrypting of the human
genome. The democratization of sophisticated techniques
that render whole-genome studies temporally and financially
accessible, has contributed to the uptake of epigeneticRIC), University of Copenhagen, Ole Maaløes Vej 5, DK-2200
vier B.V. This is an open access article under the CC BY-NC-ND
b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 1 6 6e1 7 6 167approaches. This omnipresent use of the “epigenetics label”
has made it increasingly hard to pinpoint its exact definition
and technical limitations.
In the midst of an elusive, broad collection of phenomena,
partially contradictory definitions and loosely related disci-
plines, it is sometimes difficult to concentrate on the question
if and how epigenetics might one day result in a practical
application and if passive observation will give rise to active
intervention [1] [Fig. 1].What are we actually talking about?
As trivial as it might sound, this is quite a legitimate question.
While every scientist and educated layman has a more or
less clear notion of epigenetics, pinning down a concrete,
palpable definition turns out to be an almost Sisyphean task.
To all appearances, the minimal common denominator of
various definitions seems to coalesce around “functionally
relevant changes in gene expression that are not due to mod-
ifications of the underlying DNA sequence” [2]. Technically,
this embraces a substantial amount of biochemical signaling
pathways inside a cell, including the binding of any tran-
scriptional modulator to a promoter and subsequent quanti-
tative changes in gene transcription. Most sources agree that
these changes in gene function have to happen “via chemical
modifications ofDNAor histones”, narrowingdown thefield of
action to a finite set of precise biochemical events (Box1).
Box 1
Classical “epigenetic” chromatin marks.DNA modifications
DNA methylation (5 mC)
 Methyl group added on cytosine or adenine bases
 Mainly studied in CpG context, might be frequent in
other sequences
 Leads to gene silencing via DNA compaction, recruit-
ment of transcriptional repressors and exclusion of
transcriptional activators
 Initially deposited by de novo methyltransferases
guided by sequence, DNA binding proteins, long non-
coding RNAs or RNA interference
 Mitotically inherited in a semi-conservative manner
via maintenance methyltransferases
 Enzymatic activities responsible for demethylation in
mammals are still controversial
DNA hydroxymethylation (5 hmC)
 Found in many mammalian tissues
 Effect on gene expression still relatively unknown
Histone modifications
- Post-translational modifications of specific serine,
lysine and arginine residues of the histone amino-
terminal tail or histone variants- Histone-modifying enzymes are recruited by specific
DNA-sequences or guided intermediate protein and/or
RNA complexes or RNA interference
- The replication and inheritance of histone modifica-
tions during mitosis is unclear
 Acetylation
B Associated with transcriptional activation
 Methylation
B Mono-, di- or tri-methylation
B Either repression- or activation-associated,
depending on the targeted residue
 Phosphorylation
B Associated with transcriptional activation
 Ubiquitination
 Sumoylation
B Associated with transcriptional repression
 Histone variants
B macroH2A is associated with inactive chromatin
B H3.3 might be mitotically heritable and accumu-
lates in active chromatinAre DNA repair and the associated histone variants, like
gH2AX, an epigenetic event then [3]? Finally, the real aficio-
nados insist on integrating the notion ofmeiotic and/ormitotic
heritability of epigenetic marks and effects [2e5]. Yet, herita-
bility remains a major source of confusion, even in its most
basic form, cellular division.While themitotic transmission of
DNA methylation via maintenance DNA-methyltransferases
is quite well-established and studied, the shuffling and
redistribution of histones, histone modifications and variants
following cell division remain elusive [3]. Further bias has
arisen through the widespread impact of a collection of sci-
entific articles strongly suggesting the repercussion of per-
sonal experience and environmental influences on offspring,
shifting the attention to meiotic heritability [6,7]. But so far no
mechanistic model can explain how chromatin-encoded in-
formation could escape the genome-wide demethylation
during the preimplantation stage [3,4,8]. Given the dilemma,
the NIH Roadmap Epigenomics Mapping Consortium broad-
ened the definition to “also stable, long-term alterations in the
transcriptional potential of a cell that are not necessarily
heritable”, though no consensus exists on the inferior limit of
“long-term” [9].
From that point on, things become gradually confusing.
For instance, many publications investigating epigenetic
mechanisms also include noncoding RNAs [3,8,10]. The
latter divide on either side of the arbitrary 200 nucleotides
length-limit into small and long noncoding RNAs (lncRNAs),
where the first group is further subdivided into a long list of
functional classes and the second one mainly unexplored
[11].
Most small noncoding RNAs excel indeed in short-term
post-transcriptional modulation of gene activity, although
not necessarily in an especially durable way nor via chromatin
states. Only Piwi-interacting RNAs are said to silence retro-
transposons in germ line cells through interaction with
methyltransferases [12]. Similarly, microRNAs can prompt the
Fig. 1 e Can we fix the epigenetic landscape? Altered epigenetic modifications are associated with many diseases, but what are
the realistic clinical applications of epimedicine?
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termed RNA-directed DNA methylation (RdDM) … in yeast
[3,4,8]. Its existence in humans is yet speculative [11].
Recent major technical advances in whole-transcriptome
sequencing, revealing that the major part of the genome is
transcribed but not translated, shifted the interest towards
lncRNAs [13].
This led to gigabytes of data and ten thousands of un-
studied transcripts. Several specimens are indeed able to re-
cruit chromatin-modifying complexes to specific genomic
locations, induce the depositing of epigenetic marks as well as
durable changes in gene expression [2,3,8]e the X inactivation
process un female mammals is without doubt the most
impressive example [14].
However, becauseof several artifact-prone in vitro studiesof
RNA-protein interactions [15,16], it was over-hastily assumed
that themajorityof all longnoncodingRNAsactedas guides for
chromatin-associated proteins, resolving en passant the mys-
tery of how the adequate subset of binding sites of one protein
are chosen among thousands of identical sequences according
to one cellular context [10]. A fervid polemic ensued, which
disemboguedmoreor less in the temporary consensus that it is
way to early to attribute any general function to the over-
whelming amount of uncharacterizedmolecules, and that no,
lncRNAs are not epigenetic factors.
In the meantime, more molecules and biochemical events,
able either to modify gene expression post-transcriptionally
or to perpetuate a modification over cell division and some-
times both, cluster around the gates of epigenetics. In parallel,
the definition gradually drifts away from the original center
andmonopoly of information, the chromatin, now potentially
including RNA editing, prions and modifications in non-
histone proteins such as microtubules and even organelles
or the cellular membrane [10,17].We note two fundamental problems here, hampering our
quest of a clear definition. One is semantic in nature and re-
sults from confusion around the different elements of epige-
netics. There are epigenetic effects e heritable changes in gene
function for equal DNA-sequences, whatever the underlying
mechanism. There are epigenetic marks e covalent modifica-
tions of DNA or chromatin proteins. And finally, there are all
the putative intermediates, proteins or RNA, leading frommark
to effect.
The other problem is the gap in our knowledge. Cases
where mark, intermediates and effects are well-characterized
are rare and it remains mysterious how the initial marks are
established and specific modifications targeted to precise se-
quences [3].Journey to the past
But why is such a popular concept difficult to define? A brief
journey to the past could shed some light on the current
confusion. The original concept of epigenetics can be traced
back to the embryologist and philosopher Conrad Wadding-
ton in 1942 [18]. Despite the discovery of the basic laws of
heredity and chromosomes [3], “genes” were yet an exclu-
sively theoretical principle, incarnated by an elusivematerial
support. Their analysis relied solely on a top-down principle,
based on visible phenotypic traits. Genetics and embryology
were two completely separate fields e only two years after
Waddington's publication, the Avery-MacLeod-McCarty
experiment provided concrete proof that DNA, and not pro-
teins, represented the actual support of genetic information
[19,20].
Hence, Waddington's definition is a conceptual, theoret-
ical one. He proposed the epigenotype as the black box
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processes and causal mechanisms by which the genes of the
genotype bring about phenotypic effects”, and its study as
epigenetics, the fusion of epigenesis, a synonym of embryonic
development, and genetics [18,19]. From our “modern” point
of view, Waddington's epigenetics incorporated the field of
genetic regulation, with all its transcription factors, en-
hancers, repressors, feedback loops and molecular path-
ways. By uniting embryology and genetics, Waddington
created somehow what we would nowadays call develop-
mental genetics [8,19].
The following decades brought about an exponential in-
crease in understanding of the molecular nature of genes
and their expression, including transcription and trans-
lation. Epigenetics however remained devoid of any molec-
ular mechanisms until themid-seventies, although regularly
appealed to in order to substitute for the mysterious “auxil-
iary mechanisms” that drove the “primary genetic material”
into a final phenotype [8]. Then, gradually, molecular evi-
dence started to accumulate.
DNAmethylationwas discovered in 1950 [8,21] and in 1969,
Griffith and Mahler initially suggested that it might be
responsible for memory e literally e as a mechanism to
encode long-term memories in brain cells [22]. The idea that
DNA methylation could rather influence gene expression was
proposed in 1975 [5,23].
In turn, the interest in the roles of the large panel of his-
tone modifications in the modulation of gene expression is
mainly 21st century material, though their identification
spreads from 1964 (acetylations, methylations) [24,25] to
2003 (sumoylations) [26]. The definitive link between histone
amino-terminal tail modifications and gene expression
regulation wasmade in the early eighties and the discoveries
of other modifications exploded from 1996 on [3]. Concomi-
tant with the new millennium, the terms “histone code” and
“epigenetic code” were born [3,27].
As a consequence, the transition from phenomenon to
molecular facts has greatly shifted and narrowed the defi-
nition of epigenetics from its initial conceptual nature to a
way more mechanistic and molecular one, leading to the
opportunistic reinterpretation of the Ancient Greek prefix
“epi-“ as “on top of the DNA molecule” [4,19]. The compo-
nents have been substituted to the phenomenon they were
meant to explain.
The modern vision of epigenetics is a modular one. One
brick corresponds to changes in gene expression unrelated to
changes in the underlying DNA sequence. One comprises a
collection of chemical modifications of DNA and proteins.
Another one represents the concept of heritability or dura-
bility. Depending on the biological process in question, the
different modules are not forcefully a hundred percent
compatible; rather a specific selection has to be chosen to
match the facts.
Recently, some colleagues have distanced themselves from
an overzealous use of the term, preferring concrete terms like
chromatin-associated modifications. For the sake of clarity
and if not specified otherwise, we will restrict ourselves to
“classical” epigenetics, namely DNA methylation and histone
marks, for the rest of the review.Day-to-day epigenetics
The establishment of epigenetic chromatin marks is part and
parcel of many fundamental processes during the life of a cell
or a multicellular organism. The four most prominent ones
are cellular differentiation, genome stability, imprinting and
adaption to the environment.
Cellular differentiation
Although the author ignored the exact nature of genes and
their relationship with RNA and proteins, Conrad Wadding-
ton's famous epigenetic landscape is a visual metaphor for the
embryonic development and cellular commitment [28]. He
portrayed a totipotent cell rolling down a hill, representing
gene networks, epigenotype and environment, leading to the
terminally differentiated state of a specific function-related
subset of gene expression at the bottom of the mountain [2,8].
The importance of epigenetic mechanisms during cellular
differentiation was further stressed by David Nanney in the
late 1950s who hypothesized that “epigenetic systems, regu-
late the expression of the genetically determined potential-
ities” [8,29]. Interestingly, it is Nanney who added the
“stability/heritability” compound to Waddington's epigenetic
principle, in order to tell the difference from “more trivial,
immediately reversible phenotypic mechanisms” [1]. Around
1970, the assumption that all cells of one organism contained
the same DNA crystallized into certainty, thanks to somatic
nuclear transfer experiments, underlying the need for an
interpretation toolbox [3,23].
The classical epigenetic marks are indeed the felt-tip
markers and whiteout of the static DNA instruction manual,
stably garnishing during development required genes with
active marks, and compacting the chromatin of the undesir-
able ones with astonishing precision [2,4]. Ultimately, the
simplemethylation profile suffices to distinguish a Th1 from a
Th2 helper cell [30]. Vice versa, the natural genesis of plurip-
otent embryonic stem cells in the inner cell mass is preceded
by a genome-wide demethylation step, while the artificial
reprogramming of terminally differentiated cells into induced
pluripotent stem cells (iPS) is promoted by inhibitors of
methyltransferases and histone deacetylases, thus demon-
strating the amazing plasticity of genetically identical cells
[8,31]. Still, we ignore how the differentiation-related marks
are disposed in first place.
Genomic stability
Evolution is a tinkerer and evolution not about building the
theoretically optimal construct but about putting up in the
best possible way with the opportunities and inconveniences
that showup en route [32].We have to keep inmind that a huge
proportion of the genome is of parasitic origin [33]. For
example, retrotransposons represent roughly half of the
human genome. Although these selfish DNA elements might
sometimes lend a hand to evolutionary innovation, the cell
has got its hands full bridling centromeres, telomeres and
transposable elements in order to warrant the correct
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recombination, transposition and insertional mutagenesis
[4,34]. Thus, a stable, mitotically transmissible chemical lock
sounds like a convenient tool and the major part of DNA
methylation in vertebrates seems indeed to be correlatedwith
repetitive and retroviral sequences [3].
Gene dosage compensation is a prime example of epige-
netically orchestrated genomic stability [4]. X chromosome
inactivation in female mammals calls on the services of an
armada of redundant chromatin modifications e DNA
methylation,histonevariantsandhistone tailmethylationeas
well as their direct and indirect providers:methyltransferases,
long noncoding RNAs and the PRC2 complex [4,14].
Imprinting
Imprinting refers to the monoallelic expression of a gene
depending on its parental origin [35,36]. In other words, only
the maternal or paternal version is expressed while the other
is extensively silenced. This applies to about 1% of human
genes and its putative advantages remain a major evolu-
tionary mystery entwined by many theories [2,8]. Imprinted
loci tend to be growth- and development-associated, such as
the best studied example, the Igf2/H19 locus [3,8,10]. In fe-
males, imprints are a priori placed during folliculogenesis and
in males during fetal development and consist concretely in
the selective methylation of the DNA andmarking of histones
with repressive tags [4].
Environmental adaption
Phenotype ¼ genotype þ epigenotype þ environment.
That is the original equation of the epigenetic landscape,
thus assigning to the environment an essential role in em-
bryonic development. Nowadays, epigenetics are often dis-
cussed in the context of environmental impacts on genomic
function and output. A notorious example of an environment-
directed and epigenetic-mediated phenomenon is the devel-
opment of the bee larva into either a worker or a queen,
exclusively mediated by the differential methylation of iden-
tical genes triggered by diet and available space [37,38].
Similarly clear-cut examples are difficult to find in humans,
although spatial and environmental cues are crucial for early
embryogenesis and maturation [39,40]. The requirement for
reactivity and cellular plasticity to adapt to alterations in the
physical and chemical environment is clear [2,41], and the
mutation/selection process of DNA too slow. The human or-
ganism is equipped with an efficient hormonal signaling
system and a horde of molecular sensors, such as heat shock
proteins, allowing rapid responses to exterior stimuli. How-
ever, these types of adaptions are relatively ephemeral and
epigenetic mechanisms have the reputation of perpetuity.
Further studies are required to understand how environ-
mental factors might lead to precise long-term modifications
in chromatin structure and function [42].
During their lifetime, monozygotic twins drift apart at the
scale of their epigenome, an attractive explanation for the
development of different phenotypic and behavioral traits, as
well as the unequal susceptibility to diseases [43]. What arethe possible causes? Fortuity is a by all means a plausible
answer. Environmentally directed epigenetic adaption is the
answer we want to hear, though. Nevertheless, most studies
agree that the critical period of responsiveness to the envi-
ronment, eventually being translated into long-lasting chro-
matinmodificationswith an impact on an individual's life, lies
within the embryonic development [18]. Notably, methylation
has been shown to be sensitive to the maternal environment
[2,4]. While chromatin marks acquired during this period
affect the individual, the epigenetic storage of information to
be passed down to progeny has logically to take place during
germ cell development, i.e. in utero for females but
throughout lifetime in males, albeit the mechanisms are un-
known [2,4,6,7].Epigenetics and disease
As epigenetic chromatin marks play well-established roles in
fundamental physiological processes, there is no surprise that
their misbehavior can have fatal consequences.
Obvious and well-studied examples are imprinting disor-
ders, in which imprinted genes are aberrantly expressed due
to the lack of sufficient silencing via repressive chromatin
marks; such as the PradereWilli, Angelman, Beck-
witheWiedemann and SilvereRussel syndromes, consisting
in neurodevelopmental disorders and growth abnormalities
[2,10]. As the establishment of genomic imprints occurs dur-
ing early embryonic development and could easily be
disturbed by environmental factors, this raises some concern
about human assisted reproductive technologies [4,10].
Another scenario with a relatively clear link between cause
and consequence arises from mutations of the de novo DNA-
methyltransferase DNMT3B in form of the rare
Immunodeficiency-Centromere instability-Facial anomalies
(ICF) syndrome, characterized by hypomethylation of many
loci and aberrant chromosomal configurations [44]. Further-
more, mutations of the methyl-binding protein MECP2 lead to
the neurodevelopmental disease X-linked Rett syndrome
correlated to lacking transduction of methylation marks into
spatial DNA-organization [10].
Changes in the epigenetic profile have been described for
numerous pathologies compared to healthy controls, for
example cardiovascular disease, mental disorders or amyo-
trophic lateral sclerosis [45e47]. In contrast to the previous
examples, it remains unclear though how those defective
marks arise and to what extend they are the cause or the
collateral damage of the disease state.
The most extensively studied pathological case of DNA
methylation is without surprise cancer, resulting in the
emergence of a separate research field entitled cancer epige-
netics [8,10]. Markert suggested already in 1968 that cancer
could be due to gene activity being misprogrammed by
epigenetic mechanisms [48]. In 1982, Feinberg and Vogelstein
identified the first concrete epigenetic divergence in cancer
and described the hypomethylation of a set of genes in several
primary tumor types [49]. Both hypomethylation and hyper-
methylation inmany cancer types have since been thoroughly
identified, analyzed and made publicly available by the NIH-
founded Cancer Genome Atlas (TCGA) research network
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ply of deleterious secondary effects: hypomethylation un-
leashes oncogenes, multiresistance genes, pericentromeric
satellite sequences or retrotransposable elements, while
hypermethylation silences tumor suppressor genes [10].
Yet, pure observation is rapidly unsatisfying and, under
financial and publication pressure, the desire to press the
handy on/off button made of DNA methylation is omni-
present. The unwritten consensus of the last paragraph of
every recent publication dealing with any epigenetic-related
phenomenon (and the choice is large, considering the scat-
tering of the notion) is to sell it as a promising biomarker or as
a novel therapeutic target [10].Epimedicine
Like someone trying to learn to play billiard from just
watching, there is an intertwined triad in Science conducting
the transition from observation to intervention: deducing the
rules, predicting the next move and finally playing. By anal-
ogy, in the case of epigenetics, they could be renamed epide-
miology, prognosis and epitherapy [Fig. 2].
Guessing the rules: epigenetics and epidemiology
Molecular genetics and the discovery of genetic information
revolutionized centuries of empirical and organ-focused
medicine in a couple of decades into an era of molecular
medicine [10]. The ensuing expectations and speculations
climaxed fourteen years ago, when after years of intenseFig. 2 e The three stages of Science: Obselabor, the first drafts of the entire sequenced human genome
were published [52,53]. Scientists affirmed that this would
“revolutionize the diagnosis, prevention and treatment of
most, if not all, human diseases” and many believed that the
mutational program of complex diseases would be decrypted
and subsequently repaired by genetic therapy [10].
Despite the undeniable achievements of genome-wide
association studies (GWAS), a certain feeling of disappoint-
ment quickly followed the initial excitement. Fixing genes
turned out to be way trickier than expected and suffered
both a serious setback and damage to its public image
through a few unexpected side effects like the death of Jesse
Gelsinger and cases of leukemia after treating X-linked se-
vere combined immunodeficiency using adenoviruses
(though Alain Fischer was awarded the well-earned Japan
Prize last year) [54,55]. Moreover, the understanding of
complex and non-Mendelian diseases progressed only
scarcely e no clear-cut sets of mutations or genetic variants
could be attributed to autism or diabetes and even patients
with monogenic disorders displayed fluctuating symptoms
and disease severity. DNA was obviously not the sole perti-
nent reference to gain insight into the molecular un-
derpinnings of disease.
The knight in shining armor arrived in the form of epige-
netics and suddenly the shortcomings of genetics meta-
morphosed into the sales pitch for epigenetics e as genes do
not hold all the keys to disease, epigenetics will. They were
proclaimed the “biggest revolution in biology that is going to
forever transform the way we understand genetics, environ-
ment, the way the two interact and what causes disease” in
2007 [56]. This sounds strangely familiar, doesn't it?rvation, Prediction and Intervention.
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connection between environmental effects and disease phe-
notypes, including nutrition, chemical and physical in-
fluences but also e a novelty compared to genetic studies e
social factors [57e59]. The first cluster of Epigenetic Associa-
tion Studies (EWAS) was published around 2010 [60], fueled by
initial high-impact publications, such as the much-quoted
Swedish harvest data putting forward a transgenerational
effect of diet mediated by sperm or the link betweenmaternal
care and anxiety in rats [7,61].
Where are the flaws then?
One complication is the logical consequence of the defi-
nition dilemma of epigenetics: what exactly should we look
for and above all, where should we stop looking? Where is
the limit of functional significance and where starts
randomness and background noise? Any study can only
consider a limited amount of variables, thus the argument
that not enough factors were taken into consideration, just
like DNA not being sufficient to understand disease, will
always apply. DNA methylation of promoter regions, for
instance, is currently the widest studied epigenetic phe-
nomenon for technical reasons, however one might argue
that they are meaningless as long as non-CpG DNA
methylation, histone marks and noncoding RNAs are not
taken into account in parallel [60].
Other problems are identical to those encountered by
genetic approaches. Just like various sets of mutations can
lead to similar disease phenotypes, why would there be a
unique set of epimutations corresponding to one symptom?
Furthermore, like every nascent scientific domain, epige-
netics is currently in a state of technological trial and error.
Regarding the state of the art, an exhaustive description and
qualitative comparison of current technologies and data
analytical approaches for epigenomics can be found in the
review by Klaas Mensært and colleagues [62]. As much as the
notion, the associated technology is under construction and
still imperfect e not enough time has passed yet to inspect
reproducibility, agree on foolproof controls and quality-
control steps, and rule out artifacts. An armada of
different methods is in use and comparing results obtained
by different strategies and platforms is difficult, nay
impossible [60]. In parallel, the explosion of available data of
the last decade, thanks to the advent of high-throughput
sequencing technologies and the considerable drop in cost
of the latter, has triggered a boom in bioinformatics and
analytical methodologies. However, algorithms are as
manifold as bench practices and not unconditionally com-
parable e with the difference that a considerable proportion
of biologists is not exactly up-to-date with the rapidly
evolving amount of tools and that a reasonable bio-
informatic training was only recently integrated into the
undergraduate programs.
But EWAS have also their very own set of challenges,
different from genetic studies. The main hurdle is the spatio-
temporal variability of the epigenome within one individual.
DNA is static, identical in all cells of the organism and e
modulo some eventual mutations over time e remains also the
same during the entire lifetime of the organism. Because of its
fundamental role in cell fate, the epigenome in contrast isextremely cell-type specific and because of its plasticity and
sensitivity to environmental stimuli, it tends additionally to
change over the years [2,60,63]. The first corollary is that the
precise cell type and cell purity matter. Studying the epige-
netic compound of Parkinson's disease using keratinocytes
won't make much sense, but getting hold of human dopami-
nergic neurons of the substantia nigramight be linked to a few
inconveniences. Evidently, this impedes as well the compar-
ison between individuals and renders the scaling-up of
studies complicated by lack of equivalent material e in cell
type, age and maybe environmental context [2,60]. Tradi-
tionally, whole blood samples were collected for genetic
cohort studies, like the broadly used 1958 British Birth Cohort
Study, yet blood is a heterogeneous tissue and moderately
representative for most organs. Nevertheless, this collection
has been used to correlate childhood socio-economic status
and adult DNA methylation [59].
Moreover, epigenetic epidemiology lacks a fundamental
benchmark. Genetics have their hg38 and MM10 e regularly
updated “reference genomes” e but there is no absolute
reference DNA-methylome to relate to. Considering above-
mentioned issues of cell-specificity and variability, a gigantic
number of samples would be required to achieve a halfway
representative mean of epigenomes and an idea of the degree
of inter-individual differences, a methylated equivalent of
genetic polymorphisms [2,60].
Nonetheless, numerous big projects and international
collaborations have been launched in order to tackle the task:
the European Union Blueprint Consortium is trying to deci-
pher the epigenome of hematopoietic cells, with the goal to
furnish about hundred reference epigenomes [64], the NIH
Roadmap Epigenomics Mapping Consortium focuses on stem
cells and primary ex vivo tissues [9,65] and the International
Human Epigenome Consortium has the modest aim to “un-
derstand the extend to which the epigenome has shaped
human populations over generations and in response to the
environment” by decrypting at least 1000 epigenomes during
the next decade [66].
The future will show, how realistic those plans are.
Predicting the moves e a tale of biomarkers
On a daily basis, studies are published introducing a
particular noncoding RNA or methylation pattern as the
ideal “biomarker” for a specific type of cancer, often without
any further investigation of the functions and mechanisms
of the candidates. This notion goes hand in hand with the
popular concept of “personalized medicine” and the idea
that one day, each patient will be treated with a tailor-made
cocktail of drugs, corresponding to his precise (epi)genomic
profile.
True, each cancer can be considered as unique e an
exclusive collection of mutations and epimutations e and the
good correlation of thousands of different sets of biomarkers
with thousands of disease variations is probably correct.
Sequencing large parts of the (epi)genome or even tran-
scriptome of a patient is not that unconceivable either, and
might greatly improve the current deficiencies in patient
stratification both for therapy and cohort studies. There is one
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different treatments or drug combinations. At least, not yet.
Playing the game e epitherapy
The theoretical attractiveness of targeting chromatin modifi-
cations lies in their greater reversibility and natural flexibility
compared to DNA mutations, making them in principal a
more accessible point of attack [2,4,10].
Companies aiming to develop epitherapeutic drugs, prin-
cipally targeting DNA methylation and histone modifications,
have sprouted over the last years and the major pharmaceu-
tical concerns branched off substantial financial resources
into the creation of novel departments. Most applied research
efforts focus currently on cancer therapies and all concrete
applications and exciting treatments are restricted for now to
cancer treatment. This does not come as a surprise e cancer
research benefits historically from a particular background of
public attention, economic weight, financial resources and
huge quantities of available research material, from cell lines,
frozen tumor samples to in vivomodels. Hence, the cancer field
has always been at the forefront when it comes to the imple-
mentation of new technologies and treatment strategies [10].
The purpose of this review is not to present an exhaustive
list of available drugs or those at various stages of clinical
trials, most of which can be found in the Orange Book of the
US Food and Drug Administration (FDA) and various reviews,
thus we will content ourselves with a quick, representative
overview [67,68].
Shoot first, ask questions later, is not an unusual approach
in the history of drug discovery. 5-azacytidine, alias Vidaza on
the market [69], was empirically known for cytotoxic effects
on cancer cells since 1968, but its actual role in inhibiting DNA
methylation was only established a decade later [68e70]. Its
derivative, 5-aza-20-deoxycytidine (Decitabine) is used for the
treatment of hematological malignancies and similar analogs,
such as Zebularine, are at the stage of clinical trials [8,68].
Similarly, valproic acid was used for nearly half a century to
treat neurological diseases like epilepsy under the name of
many brands before it turned out to be also a histone deace-
tylase (HDAC) inhibitor and thus of interest for cancer ther-
apy, where it is currently investigated [71].
After looking, this time on purpose, for modulators of
epigenetic mechanisms, the first HDAC inhibitor in form of
superanilohydroxamic acid (SAHA, marketed as Vorinostat)
was approved by the FDA as a third line treatment against T
cell lymphoma [72] [Fig. 3]. Taking into account the consider-
able delay between the identification of molecules with po-
tential therapeutic applications and their approval as drugs,
from proof of mechanism to proof of concept, as well as the
high failure rate, most treatment strategies launched by the
companies born during the last decade are yet at various
stages of (pre)-clinical trials: mainly peptides acting as in-
hibitors of diverse DNMTs, HATs or HDACs but also some
antisense oligonucleotides against the RNA precursors of the
latter [68]. The following ten years will without doubt witness
an accumulation of epigenetic cancer drugs on the market.
However, we will probably have to wait for a couple of more
decades before an objective judgment of their usefulness and
efficiency becomes pertinent [2].To date, the targeting of DNA and histone modifications
suffers from the same flaws than any kind of drug adminis-
tration. The main one is the problem of precise targeting e at
the level of the organism, when it comes to aim only at cancer
cells but avoid collateral damages in their normal neighbors;
and at the level of the chromatin, when it comes tomodify the
state of only specific genomic loci. While tissue-tropism is
vaguely achievable for many drugs, an inhibitor of a methyl-
transferases will inevitably lower the methylation levels
genome-wide. Reaching this degree of precision requires first
a way more detailed level of knowledge on how chromatin
marks are recruited to specific sequences in specific cellular
contexts. It is by allmeans conceivable to act one day on a long
noncoding RNA responsible for guiding amethyltransferase to
one locus, for now however, no such concrete approaches
exist.
There is an unavoidable gap between the researcher and
the clinician. The latter has a somehow more humble
approach of the living than the biologist. Empirical trial and
error as well as not knowing everything is an acceptable
option; and questioning compulsorily all underlying
mechanisms is not a necessity. From the clinical point of
view, epigenetic cancer therapy has not the slightest pre-
tention to be better, safer or cheaper than existing treat-
ments, rather it is meant to be complementary, to enrich
the arsenal. Cancer is a nasty, constantly changing enemy
with many resources e having more than one string to
one's bow won't be amiss. Most trials don't focus uniquely
on epigenetic treatments, by the way, but rather on com-
binations of different compounds targeting different
pathways.
Who is next, on the list of potential targets for
epitherapeutics?
Several trials are being conducted in the context of human
immunodeficiency virus (HIV) infections [73]. Inflammation
maybe, more specifically reversible diseases such as inflam-
matory bowel disease (IBD), and metabolic diseases linked to
tissues presenting a rapid turnover, allowing thus to affect the
adult stem cell population.Conclusions
The big picture
Pointing out that no cellular phenomenon exists indepen-
dently of others certainly lacks any originality. Yet in the
context of the popularity of epigenetics, it might be appro-
priate to remember that not only the notion is vague, but also
that clearly defined components are just another brick in the
wall and that one modification may gain functional impor-
tance only if it co-occurs with other changes [60].
Since the hype seems to have cooled down across the last
five years, the latest trend is integration [2,3]. Public genome-
scale resources call for combining DNA sequence, epi-
genomic, transcriptomic and proteomic data for each sample
[60]. Also, old data are resurrected. To the general puzzlement,
many disease-correlated genetic variations locate to non-
coding regions and were put on ice. In the light of long non-
coding RNA, these variations are reconsidered.
Fig. 3 e Epigenetic chromatin modifications and currently available treatments acting on them. Both DNA and histones can
carry many chemical modifications that alter the chromatin state and the expression of genes. They are deposited, altered and
removed by a panoply of enzymes. These in turn are regulated by many factors and interact with various molecules, including
noncoding RNAs. Several drugs specifically target these enzymes.
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For now, the effect of studies relating the transmission of
maternal skills and the link between socio-economic status
and suicide, ranges from questionable over inexplicable to
fascinating with a taste of Lamarckian theory, which can be
considered as rather harmless [8,61,74].
Even so, it is a legitimate question, what the long-term
effect of epigenetics will be on the human society [2]. Unde-
niably, genetics have profoundly changed our perception of
the interplay of human health and environment. Nowadays,
we cover ourselves in sun-cream, fear genetically modified
vegetables, and anti-smoking laws and campaigns are omni-
present to the extend that movie posters for Gainsbourg: A
Heroic Life were banned from the Parisian metro stations
because they featured the eponymous French singer with his
hallmark e a cigarette. Maybe our slightly paranoid society
will progressively include epigenetic hazard into risk assess-
ments and add a detailed health record of the environmental
exposures, diet and social surroundings of early life stages
into the health record booklet [2,42].Prenatal tests for genomic abnormalities had raised the
fear of eugenics and genetic discrimination, as depicted by the
1997 dystopian film Gattaca. In conformity with our current
code of ethics, the genetic determinism was properly dis-
missed in the moral of the story, rehabilitating randomness
and free will.
But what kinds of dangers await a new society that believes
in the heritability or behavioral programming by parental drug
addiction, domestic violence or child abuse? [8,74].
The cycle of knowledge
Oddly, we currently witness a certain reemergence of the pre-
seventies state of mind when it comes to epigenetics, specif-
ically to the issue of inter-generational heritability. During the
early post Watson-Crick era, epigenetics were invoked by
default when genetics could not provide an explanation any
more e a potpourri of phenomena above and beyond genetics
[8]. After a brief period of clarity starting in the 1990s, when the
definition of epigenetics furtively overlapped the notion of
DNA methylation, during the last 15 years, the limits of the
b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 1 6 6e1 7 6 175term have again moved out of focus by the aggregation of
components [1]. And again, epigenetics are the explanation for
happenings beyond our current understandinge development
and the passing-on of acquired traits between generations.
In an excellent essay, Robert Weinberg, one of the authors
of the famous “hallmarks of cancer” illustration, looks back on
the history of molecular cancer research. He highlights the
eventful journey of research from confusing incomprehen-
sion to the glorious years of reductionism and back to over-
whelming complexity [75]. A similar scheme seems to apply to
(epi)genetics, born into the mystery of embryonic develop-
ment and heredity, then promoted to the program governing
life before drowning in the complexity of omics. Waddington
himself was genuinely convinced that “genetics is a way of
analyzing an animal into representative units, so that its na-
ture can be indicated by a formula, as we represent a chemical
compound by its appropriate symbol”, predicting exactly the
phase of reductionism triggered by the first successes of mo-
lecular genetics [18].
Due to their popularity (epi)genetics were inevitably bound
to deceive, but the powerful comeback of complexity stems
also from a profound shift in our way to approach biological
questions, after that technological progress unlocked entirely
new horizons (high-throughput sequencing just turned 10). In
the era of omics e genomics, proteomics, metabolomics e the
angle of view on biology has radically changed from focus to
global. Instead of investigating one precise object, may it be a
gene or a species, the goal is now to provide a description of all
components of a system in parallel, assuming that many
phenomena make sense only through the study of all their
actors.
Any biological process is the result of the coordination of
myriads ofmolecules and individual decisions, and at the very
opposite side of reductionism, one might argue that only the
knowledge of the spatio-temporal coordinates of every single
molecule will allow us to fully understand the process in
question [19]. When the ENCODE data was released, some
claimed that “possibly every single molecule in the cell is
functional” [13].
Maybe in the future, with the increasing resolution and
power of data generation, analysis and modeling, all concur-
rent definitions and mechanisms will fade away and blend in
a novel vision of life e the one of Systems Biology.r e f e r e n c e s
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